相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model
Huan Zhang et al.
CANCER GENE THERAPY (2022)
Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti–PD-1 therapy: MASTERKEY-115.
Brian Gastman et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Immune checkpoint inhibitors in melanoma
Matteo S Carlino et al.
LANCET (2021)
Combination therapy with oncolytic viruses and immune checkpoint inhibitors
Matthew Chiu et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
Guan Wang et al.
NATURE COMMUNICATIONS (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma
Gayathri Vijayakumar et al.
EBIOMEDICINE (2019)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments
Jong W. Yu et al.
PLOS ONE (2018)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells
M. Fehlings et al.
NATURE COMMUNICATIONS (2017)
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer
Omid Hamid et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Local Delivery of OncoVEXmGM-CSF Generates Systemic AntitumorImmuneResponses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade
Achim K. Moesta et al.
CLINICAL CANCER RESEARCH (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
Robert H. I. Andtbacka et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Se Jin Im et al.
NATURE (2016)
The Herpes Simplex Virus Neurovirulence Factor γ34.5: Revealing Virus-Host Interactions
Douglas R. Wilcox et al.
PLOS PATHOGENS (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Sonja Kleffel et al.
CELL (2015)
Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors
Michael A. Curran et al.
CANCER RESEARCH (2009)
Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
Betty Li et al.
CLINICAL CANCER RESEARCH (2009)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors
JC Yang et al.
JOURNAL OF IMMUNOTHERAPY (2000)
分享论文
